The Heart in Diabetes (HiD brings multi-specialty world-renowned leaders in diabetes, obesity, and cardiorenal metabolic diseases interpreting state-of-the-art clinical data to improve the care of complex patients with these comorbidities.  This year, the conference will focus on incorporating emerging data including clinical trial outcomes into clinical practice. Emphasis will be given on implementing Guidelines Directed to Medical Treatment, addressing when and how to intervene early- to prevent morbidities in patients with Diabetes, and cardiorenal and metabolic diseases. The program will mix didactic presentations with cross-specialty panels with leading experts in cardiology, nephrology, endocrinology, and primary care discussing, with ample room for Q&A, optimal multi-disciplinary treatments for these patients.
 

The meeting will cover a wide range of topics including Obesity's impact on the Heart and kidneys, Women's health, ASCVD, HF, the Role of Digital & Technology, COVID-19 in Metabolic Conditions, Cardiomyopathy, Stroke prevention and treatment, Diabetes Management, Lipid Disorders, and emerging unique topics in the Cardio-renal-Metabolic Space.

 

Learning Objectives
 

Upon completion of this meeting, participants should be able to:
​
Evaluate the extent of vascular disease in diabetes, obesity, and cardiometabolic
diseases.
 

Be able to assess cardiovascular risk with imaging and biomarkers.
 

Provide comprehensive management of diabetes, addressing all CV risk factor.
 

Describe optimal use of technology specifically CGM and digital technology and
their impact on diabetes and CVD.
 

Be able to recognize hypoglycemia and its impact on the heart.
 

Evaluate stroke in diabetes and cardiometabolic conditions.
Discuss the impact of obesity and weight loss on fatty liver, the kidney, and the
heart.
 

Evaluate the evidence supporting the use of GLP1-RAs, SGLT2 inhibitors,
nonsteroidal MRAs to reduce CKD, HF, ASCVD and mortality in patients with
T2D.

 

Know new and evolving agents in the treatment of dyslipidemia.
 

Evaluate the implication to practice of new CVOTs in Cardio-Renal-Metabolic
diseases
 

Recognize the impact of diabetes and CVD on the severity of COVID-19
 

Understand women cardiometabolic diseases.
 

Discuss diabetes, CKD, CVD, and HF in diverse populations.

​

Target Audience
This educational initiative is designed for cardiologists, endocrinologists, nephrologists,
diabetologists, internists, family physicians, nurse practitioners, physician assistants,
and other healthcare clinicians interested in the prevention and treatment of diabetes,
obesity, cardiovascular disease, and associated conditions.

 

 

 

 

 

 

 

 

 

 

 

 

​